Next Article in Journal
Cryptococcus: Shedding New Light on an Inveterate Yeast
Next Article in Special Issue
The Immunologic Response to Trichophyton Rubrum in Lower Extremity Fungal Infections
Previous Article in Journal
Histoplasmosis and Blastomycosis in Solid Organ Transplant Recipients
Previous Article in Special Issue
Laser Therapy for Onychomycosis: Fact or Fiction?
Article Menu

Export Article

Open AccessReview
J. Fungi 2015, 1(2), 107-114; doi:10.3390/jof1020107

Efinaconazole Topical Solution, 10%: Factors Contributing to Onychomycosis Success

1
San Antonio Podiatry Associates, San Antonio, TX 78229, USA
2
Dow Pharmaceutical Sciences, a Division of Valeant Pharmaceuticals North America LLC, Petaluma, CA 94954, USA
3
Kaken Pharmaceutical Co. Ltd., Kyoto 607-8042, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: Theodore Rosen
Received: 1 June 2015 / Revised: 23 June 2015 / Accepted: 24 June 2015 / Published: 3 July 2015
(This article belongs to the Special Issue Cutaneous Fungal Diseases)
View Full-Text   |   Download PDF [1872 KB, uploaded 3 July 2015]   |  

Abstract

To provide an adequate therapeutic effect against onychomycosis, it has been suggested that topical drugs should have two properties: drug permeability through the nail plate and into the nail bed, and retention of their antifungal activity in the disease-affected areas. Only recently has the importance of other delivery routes (such as subungual) been discussed. Efinaconazole has been shown to have a more potent antifungal activity in vitro than the most commonly used onychomycosis treatments. The low keratin affinity of efinaconazole contributes to its effective delivery through the nail plate and retention of its antifungal activity. Its unique low surface tension formulation provides good wetting properties affording drug delivery both through and under the nail. High antifungal drug concentrations have been demonstrated in the nail of onychomycosis patients, and effectiveness of efinaconazole topical solution, 10% confirmed in two large well-controlled multicenter Phase 3 clinical studies in patients with mild-to-moderate disease. View Full-Text
Keywords: onychomycosis; efinaconazole; topical therapy; fungi; toenail onychomycosis; efinaconazole; topical therapy; fungi; toenail
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Pollak, R.A.; Siu, W.J.J.; Tatsumi, Y.; Pillai, R. Efinaconazole Topical Solution, 10%: Factors Contributing to Onychomycosis Success. J. Fungi 2015, 1, 107-114.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Fungi EISSN 2309-608X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top